Aeglea BioTherapeutics presented new Phase 1/2 data for pegzilarginase in patients with Arginase 1 Deficiency at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders in Bellevue, Washington. The new Phase 1/2 data continues to demonstrate that pegzilarginase is highly effective in sustainably lowering plasma arginine, which is the primary endpoint in Aeglea’s single, global pivotal Phase 3 PEACE trial. In addition, the new data shows that the marked improvement in plasma arginine control is accompanied by clinically meaningful responses in mobility and adaptive behavior, which are secondary endpoints in the PEACE trial. The treatment was generally well tolerated. Hypersensitivity reactions were infrequent, manageable with standard measures, and did not lead to treatment discontinuation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.